CD19-targeted CAR NK cell therapy achieves promising one-year results in patients with B-cell malignancies
Researchers from The University of Texas MD Anderson Cancer Center have reported promising results in a Phase I/II trial of 37 patients with relapsed or refractory B-cell malignancies who were treated with cord blood-derived ...
Jan 18, 2024
0
12